Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Insulins | Research article

A comparison of glycemic parameters and their relationship with C-peptide and Proinsulin levels during partial remission and non-remission periods in children with type 1 diabetes mellitus - a cross-sectional study

Authors: Gül Yeşiltepe-Mutlu, Merve Çapacı, Ecem Can, Tuğba Gökçe, Gizem Bayrakçı, Serra Muradoğlu, Said İncir, Esra Papatya Çakır, Şükrü Hatun

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Currently, there is a lack of data relating to glycemic parameters and their relationship with C-peptide (CP) and proinsulin (PI) during the partial remission period (PRP) in type 1 diabetes mellitus (T1D). The aim of this study was to evaluate glycemic parameters in children with T1D who are in the PRP using intermittently scanned continuous glucose monitoring systems (isCGMS) and to investigate any relationships between CP and PI levels.

Methods

The study included 21 children who were in the PRP and 31 children who were not. A cross-sectional, non-randomized study was performed. Demographic, clinical data were collected and 2 week- isCGMS data were retrieved.

Results

The Serum CP showed a positive correlation with time-in-range in the PRP (p:0.03), however PI showed no correlations with glycemic parameters in both periods. The Serum CP and PI levels and the PI:CP ratio were significantly higher in the PRP group than in the non-PRP group. In the non-PRP group, the PI level was below 0.1 pmol/L (which is the detectable limit) in only 2 of the 17 cases as compared with none in the PRP group. Similarly, only 2 of the 17 children in the non-PRP group had CP levels of less than 0.2 nmol / L, although both had detectable PI levels. Overall time-in-range (3. 9-1.0 mmol/L) was significantly high in the PRP group. In contrast, the mean sensor glucose levels, time spent in hyperglycemia, and coefficient of variation levels (32.2vs 40.5%) were significantly lower in the PRP group.

Conclusions

Although the mean glucose and time in range during the PRP was better than that in the non-PRP group, the glycemic variability during this period was not as low as expected. While the CP levels showed an association with TIR during the PRP, there was no correlation between PI levels and glycemic parameters. Further studies are needed to determine if PI might prove to be a useful parameter in clinical follow-up.
Literature
1.
go back to reference Chetan MR, Charlton MH, Thompson C, Dias RP, Andrews RC, Narendran P. The type 1 diabetes ‘honeymoon’period is five times longer in men who exercise: a case–control study. Diabet Med. 2019;36(1):127–8.CrossRef Chetan MR, Charlton MH, Thompson C, Dias RP, Andrews RC, Narendran P. The type 1 diabetes ‘honeymoon’period is five times longer in men who exercise: a case–control study. Diabet Med. 2019;36(1):127–8.CrossRef
2.
go back to reference Wallensteen M, Dahlquist G, Persson B, Landin-Olsson M, Lernmark Å, Sundkvist G, Thalme B. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia. 1988;31(9):664–9.CrossRef Wallensteen M, Dahlquist G, Persson B, Landin-Olsson M, Lernmark Å, Sundkvist G, Thalme B. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia. 1988;31(9):664–9.CrossRef
3.
go back to reference Mortensen HB, Hougaard P, Swift P, Hansen L, Holl RW, Hoey H, Bjoerndalen H, De Beaufort C, Chiarelli F, Danne T, Schoenle EJ. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care. 2009;32(8):1384–90.CrossRef Mortensen HB, Hougaard P, Swift P, Hansen L, Holl RW, Hoey H, Bjoerndalen H, De Beaufort C, Chiarelli F, Danne T, Schoenle EJ. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care. 2009;32(8):1384–90.CrossRef
4.
go back to reference Sullivan CA, Cacicedo JM, Rajendran I, Steenkamp DW. Comparison of proinsulin and C-peptide secretion in healthy versus long-standing type 1 diabetes mellitus cohorts: a pilot study. PLoS One. 2018;13(11):e0207065.CrossRef Sullivan CA, Cacicedo JM, Rajendran I, Steenkamp DW. Comparison of proinsulin and C-peptide secretion in healthy versus long-standing type 1 diabetes mellitus cohorts: a pilot study. PLoS One. 2018;13(11):e0207065.CrossRef
5.
go back to reference Watkins RA, Evans-Molina C, Terrell JK, Day KH, Guindon L, Restrepo IA, Mirmira RG, Blum JS, DiMeglio LA. Proinsulin and heat shock protein 90 as biomarkers of beta-cell stress in the early period after onset of type 1 diabetes. Transl Res. 2016;168:96–106.CrossRef Watkins RA, Evans-Molina C, Terrell JK, Day KH, Guindon L, Restrepo IA, Mirmira RG, Blum JS, DiMeglio LA. Proinsulin and heat shock protein 90 as biomarkers of beta-cell stress in the early period after onset of type 1 diabetes. Transl Res. 2016;168:96–106.CrossRef
6.
go back to reference Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–40.CrossRef Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–40.CrossRef
7.
go back to reference Dhahir FJ, Cook DB, Self CH. Amplified enzyme-linked immunoassay of human proinsulin in serum (detection limit: 0.1 pmol/L). Clin Chem. 1992;38(2):227–32.CrossRef Dhahir FJ, Cook DB, Self CH. Amplified enzyme-linked immunoassay of human proinsulin in serum (detection limit: 0.1 pmol/L). Clin Chem. 1992;38(2):227–32.CrossRef
8.
go back to reference Leighton E, Sainsbury CA, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes therapy. 2017;8(3):475–87.CrossRef Leighton E, Sainsbury CA, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes therapy. 2017;8(3):475–87.CrossRef
9.
go back to reference Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com, updated 2013/04/06. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.​OpenEpi.​com, updated 2013/04/06.
10.
go back to reference Derosa G, Salvadeo SA, Mereu R, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Tinelli C. Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. Diabetes Technol Ther. 2009;11(3):159–69.CrossRef Derosa G, Salvadeo SA, Mereu R, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Tinelli C. Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. Diabetes Technol Ther. 2009;11(3):159–69.CrossRef
11.
go back to reference Chiavaroli V, Derraik JG, Jalaludin MY, Albert BB, Ramkumar S, Cutfield WS, Hofman PL, Jefferies CA. Partial remission in type 1 diabetes and associated factors: analysis based on the insulin dose-adjusted hemoglobin A1c in children and adolescents from a regional diabetes center, Auckland. New Zealand Pediatric diabetes. 2019;20(7):892.CrossRef Chiavaroli V, Derraik JG, Jalaludin MY, Albert BB, Ramkumar S, Cutfield WS, Hofman PL, Jefferies CA. Partial remission in type 1 diabetes and associated factors: analysis based on the insulin dose-adjusted hemoglobin A1c in children and adolescents from a regional diabetes center, Auckland. New Zealand Pediatric diabetes. 2019;20(7):892.CrossRef
12.
go back to reference Cengiz E, Cheng P, Ruedy KJ, Kollman C, Tamborlane WV, et al. Clinical outcomes in youth beyond the first year of type 1 diabetes: results of the pediatric diabetes consortium (PDC) type 1 diabetes new onset (NeOn) study. Pediatr Diabetes. 2017;18(7):566–73.CrossRef Cengiz E, Cheng P, Ruedy KJ, Kollman C, Tamborlane WV, et al. Clinical outcomes in youth beyond the first year of type 1 diabetes: results of the pediatric diabetes consortium (PDC) type 1 diabetes new onset (NeOn) study. Pediatr Diabetes. 2017;18(7):566–73.CrossRef
13.
go back to reference Böber E, Dündar B, Büyükgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab. 2001;14(4):435–41.CrossRef Böber E, Dündar B, Büyükgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab. 2001;14(4):435–41.CrossRef
14.
go back to reference Meng X, Gong C, Cao B, Peng X, Wu D, Gu Y, Wei L, Liang X, Liu M, Li W, Su C. Glucose fluctuations in association with oxidative stress among children with T1DM: comparison of different phases. J Clin Endocrinol Metabol. 2015;100(5):1828–36.CrossRef Meng X, Gong C, Cao B, Peng X, Wu D, Gu Y, Wei L, Liang X, Liu M, Li W, Su C. Glucose fluctuations in association with oxidative stress among children with T1DM: comparison of different phases. J Clin Endocrinol Metabol. 2015;100(5):1828–36.CrossRef
17.
go back to reference Truyen I, De Pauw P, Jørgensen PN, Van Schravendijk C, Ubani O, Decochez K, Vandemeulebroucke E, Weets I, Mao R, Pipeleers DG, Gorus FK. Proinsulin levels and the proinsulin: c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia. 2005;48(11):2322–9.CrossRef Truyen I, De Pauw P, Jørgensen PN, Van Schravendijk C, Ubani O, Decochez K, Vandemeulebroucke E, Weets I, Mao R, Pipeleers DG, Gorus FK. Proinsulin levels and the proinsulin: c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia. 2005;48(11):2322–9.CrossRef
18.
go back to reference Schölin A, Nyström L, Arnqvist H, Bolinder J, Björk E, Berne C, Karlsson FA. Diabetes incidence study Group in Sweden (DISS). Proinsulin/C-peptide ratio, glucagon and remission in new-onset type 1 diabetes mellitus in young adults. Diabet Med. 2011;28(2):156–61.CrossRef Schölin A, Nyström L, Arnqvist H, Bolinder J, Björk E, Berne C, Karlsson FA. Diabetes incidence study Group in Sweden (DISS). Proinsulin/C-peptide ratio, glucagon and remission in new-onset type 1 diabetes mellitus in young adults. Diabet Med. 2011;28(2):156–61.CrossRef
19.
go back to reference Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J. Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes Care. 2019;42(2):258–64.CrossRef Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J. Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes Care. 2019;42(2):258–64.CrossRef
20.
go back to reference Steenkamp DW, Cacicedo JM, Sahin-Efe A, Sullivan C, Sternthal E. Preserved proinsulin secretion in long-standing type 1 diabetes. Endocr Pract. 2017;23(12):1387–93.CrossRef Steenkamp DW, Cacicedo JM, Sahin-Efe A, Sullivan C, Sternthal E. Preserved proinsulin secretion in long-standing type 1 diabetes. Endocr Pract. 2017;23(12):1387–93.CrossRef
21.
go back to reference Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabet Med. 2018;35(4):472–82.CrossRef Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabet Med. 2018;35(4):472–82.CrossRef
Metadata
Title
A comparison of glycemic parameters and their relationship with C-peptide and Proinsulin levels during partial remission and non-remission periods in children with type 1 diabetes mellitus - a cross-sectional study
Authors
Gül Yeşiltepe-Mutlu
Merve Çapacı
Ecem Can
Tuğba Gökçe
Gizem Bayrakçı
Serra Muradoğlu
Said İncir
Esra Papatya Çakır
Şükrü Hatun
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00681-1

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue